47,902 results match your criteria Blood[Journal]


Simultaneous bone marrow involvement by CLL/SLL and LEF1/cyclin D1-positive metastatic melanoma.

Blood 2020 Jul;136(2):258

University of Texas MD Anderson Cancer Center.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020006057DOI Listing

Sickle particulars of microparticles.

Authors:
Gregory J Kato

Blood 2020 Jul;136(2):154-155

CSL Behring.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020006303DOI Listing

Aging, inflammation, and HSC.

Authors:
James DeGregori

Blood 2020 Jul;136(2):153-154

University of Colorado Anschutz Medical Campus.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020006070DOI Listing

Aspirin in ET: will twice a day keep thrombosis away?

Blood 2020 Jul;136(2):151-153

Johns Hopkins University School of Medicine.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020005970DOI Listing

SF3B1: the lord of the rings in MDS.

Blood 2020 Jul;136(2):149-151

Josep Carreras Leukaemia Research Institute.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020005719DOI Listing

HIV antiretroviral therapy and prevention use in US blood donors: A new blood safety concern.

Blood 2020 Jul 9. Epub 2020 Jul 9.

Department of Laboratory Medicine, UCSF, United States.

Context: Antiretroviral therapy (ART) to treat and pre-exposure prophylaxis (PrEP) to prevent HIV infection are effective tools to help end the HIV epidemic. However, their use could affect HIV transfusion-transmission risk.

Objectives: Three different ART/PrEP prevalence analyses in blood donors were conducted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020006890DOI Listing

Plasma levels of growth differentiation factor 15 are associated with future risk of venous thromboembolism.

Blood 2020 Jul 9. Epub 2020 Jul 9.

K.G. Jebsen Thrombosis Research and Expertise Center (TREC), Department of Clinical Medicine, UiT - The Arctic University of Norway, Tromsø, Norway.

Growth differentiation factor 15 (GDF-15), a marker of inflammation and oxidative stress, has emerged as a biomarker for arterial cardiovascular disease. However, the association between GDF-15 and venous thromboembolism (VTE) remains uncertain. We therefore investigated the association between plasma GDF-15 levels and future risk of incident VTE, and explored the potential of a causal association using Mendelian randomization (MR). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2019004572DOI Listing

Cancer immunoediting and immune dysregulation in multiple myeloma.

Blood 2020 Jul 9. Epub 2020 Jul 9.

INSERM, Toulouse, France.

Avoiding immune destruction is a hallmark of cancer. Over the past few years, significant advances have been made in understanding immune dysfunction and immunosuppression in multiple myeloma (MM), and various immunotherapeutic approaches have delivered improved clinical responses. However, it is still challenging to completely eliminate malignant plasma cells (PCs) and achieve complete cure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020006540DOI Listing

Phosphoproteomic quantitation and causal analysis reveal pathways in GPVI/ITAM-mediated platelet activation programs.

Blood 2020 Jul 8. Epub 2020 Jul 8.

Oregon Health & Science University, Portland, Oregon, United States.

Platelets engage cues of pending vascular injury through coordinated adhesion, secretion and aggregation responses. These rapid, progressive changes in platelet form and function are orchestrated downstream of specific receptors on the platelet cell surface, and through intracellular signaling mechanisms that remain systematically undefined. This study brings together cell physiological and phosphoproteomics methods incorporating peptide tandem mass tag (TMT) labeling, sample multiplexing, synchronous precursor selection (SPS) and triple stage tandem mass spectrometry (MS3) to profile signaling mechanisms downstream of the immunotyrosine activation motif (ITAM) platelet collagen receptor GPVI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020005496DOI Listing

Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms.

Blood 2020 Jul 8. Epub 2020 Jul 8.

Memorial Sloan Kettering Cancer Center, New York, New York, United States.

Large-scale sequencing studies of hematologic malignancies have revealed notable epistasis among high-frequency mutations. One of the most striking examples of epistasis occurs for mutations in RNA splicing factors. These lesions are amongst the most common alterations in myeloid neoplasms and generally occur in a mutually exclusive manner, a finding attributed to their synthetic lethal interactions and/or convergent effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020006868DOI Listing

Expression of NrasQ61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice.

Blood 2020 Jul 8. Epub 2020 Jul 8.

Department of Medicine, Division of Blood and Marrow Transplantation, University of California, San Diego, United States.

NRAS Q61 mutations are prevalent in advanced/relapsed multiple myeloma (MM) and correlate with poor patient outcomes. Thus, we generated a novel MM model by conditionally activating expression of endogenous NrasQ61R and a MYC transgene in germinal center B cells (VQ mice). VQ mice developed a highly malignant MM characterized by high proliferation index, hyperactivation of ERK and AKT signaling, impaired hematopoiesis, widespread extramedullary disease, bone lesions, kidney abnormalities, preserved PD1 and TIGIT immune checkpoint pathways, and expression of human high-risk MM gene signatures. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020007156DOI Listing

Robust Expansion of HIV CAR T Cells Following Antigen Boosting in ART-Suppressed Nonhuman Primates.

Blood 2020 Jul 2. Epub 2020 Jul 2.

Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, Washington, United States.

CAR T cells targeting CD19+ hematologic malignancies have rapidly emerged as a promising, novel therapy. In contrast, results from the few CAR T-cell studies for infectious diseases such as HIV-1 have been less convincing. These challenges are likely due to the low level of antigen present in ART-suppressed patients in contrast to those with hematologic malignancies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020006372DOI Listing

A splenic lymphoma/leukemia with a spontaneous blast decrease without treatment.

Blood 2020 Jul;136(1):148

Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020005728DOI Listing

Occupy BTK: the key to controlling CLL.

Blood 2020 Jul;136(1):4-6

The University of Texas MD Anderson Cancer Center.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020005877DOI Listing

Oncogenesis by E2A-PBX1 in ALL: RUNX and more.

Authors:
Jonathan D Licht

Blood 2020 Jul;136(1):3-4

The University of Florida.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020005879DOI Listing

Create a healthy diet after transplant!

Authors:
Takanori Teshima

Blood 2020 Jul;136(1):8-9

Hokkaido University.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020006611DOI Listing

Mutant CALR functions: gains and losses.

Blood 2020 Jul;136(1):6-7

University of Cambridge.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020005805DOI Listing

Haematopoietic Cell Transplantation in Chronic Granulomatous Disease: a Study on 712 Children and Adults.

Blood 2020 Jul 2. Epub 2020 Jul 2.

Newcastle University, United Kingdom.

Chronic Granulomatous Disease (CGD) is a primary immunodeficiency resulting in life-threatening infections and inflammatory complications. Allogeneic hematopoietic cell transplantation (allo-HCT) can cure patients, but indication to transplant remains controversial. We performed a retrospective multicentre study on 712 patients with CGD undergoing allo-HCT transplanted in EBMT centres between 1993 and 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020005590DOI Listing

CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas.

Blood 2020 Jul 2. Epub 2020 Jul 2.

Washington University, St. Louis, Missouri, United States.

NK cells are a promising cellular immunotherapy for cancer. Cytokine-induced memory-like (ML) NK cells differentiate after activation with IL-12, IL-15, and IL-18, exhibit potent anti-tumor responses, and safely induce complete remissions in patients with leukemia. However, many cancers are not fully recognized via NK cell receptors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020006619DOI Listing

vWF maturation and release are controlled by two regulators of Weibel-Palade body biogenesis: exocyst and BLOC-2.

Blood 2020 Jul 2. Epub 2020 Jul 2.

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States.

von Willebrand factor (vWF) is an essential hemostatic protein that is synthesized in endothelial cells and stored in Weibel-Palade bodies (WPBs). Understanding the mechanisms underlying WPB biogenesis and exocytosis could enable therapeutic modulation of endogenous vWF, yet optimal targets for modulating vWF release have not been established. Since biogenesis of lysosomal related organelle-2 (BLOC-2) functions in the biogenesis of platelet dense granules and melanosomes, which like WPBs are lysosome-related organelles (LROs), we hypothesized that BLOC-2-dependent endolysosomal trafficking is essential for WPB biogenesis and sought to identify BLOC-2 interacting proteins. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020005300DOI Listing

Single cell analyses and machine learning define hematopoietic progenitor and HSC-like cells derived from human PSCs.

Blood 2020 Jul 2. Epub 2020 Jul 2.

University of Edinburgh, Edinburgh, United Kingdom.

Haematopoietic stem and progenitor cells (HSPCs) develop through distinct waves at various anatomical sites during embryonic development. The in vitro differentiation of human pluripotent stem cells (hPSCs) is able to recapitulate some of these processes, however, it has proven difficult to generate functional haematopoietic stem cells (HSCs). To define the dynamics and heterogeneity of HSPCs that can be generated in vitro from hPSCs, we exploited single cell RNA sequencing (scRNAseq) in combination with single cell protein expression analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020006229DOI Listing

Response to letter by Abdo, et al.

Blood 2020 Jul 1. Epub 2020 Jul 1.

Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK., Oxford, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020006604DOI Listing

NPM1-mutated acute myeloid leukemia: from bench to bedside.

Blood 2020 Jul 1. Epub 2020 Jul 1.

Hematology, CREO, University of Perugia, Perugia, Italy.

The nucleophosmin (NPM1) gene encodes for a multifunctional protein with prominent nucleolar localization that shuttles between nucleus and cytoplasm. NPM1 mutations represent the most common genetic lesion in adult AML (about one-third of cases) and act deterministically to cause the aberrant cytoplasmic delocalization of NPM1 mutants. Because of its unique features, NPM1-mutated AML is recognized as a distinct entity in the 2016 World Health Organization classification of hematopoietic neoplasms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2019004226DOI Listing

Procoagulant Activities of Skeletal and Cardiac Muscle Myosin depend on contaminating phospholipid.

Blood 2020 Jun 30. Epub 2020 Jun 30.

Harvard Medical School, United States.

Recent reports indicate that suspended skeletal and cardiac myosin, such as might be released during injury, can act as procoagulants by providing membrane-like support for factors Xa and Va in the prothrombinase complex. Further, skeletal myosin provides membrane-like support for activated protein C. This raises the question of whether purified muscle myosins retain procoagulant phospholipid through purification. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020005930DOI Listing

Extended clinical and immunological phenotype and transplant outcome in CD27 and CD70 deficiency.

Blood 2020 Jun 30. Epub 2020 Jun 30.

Ludwig Boltzmann Institute for Rare and Undagnosed Diseases, Austria.

Biallelic mutations in the genes encoding CD27 or its ligand CD70 underlie inborn errors of immunity characterized predominantly by EBV-associated immune dysregulation, such as chronic viremia, severe infectious mononucleosis, hemophagocytic lymphohistiocytosis (HLH), lymphoproliferation and malignancy. A comprehensive understanding of the natural history, immune characteristics and transplant outcomes has remained elusive. Here, in a multi-institutional global collaboration, we collected clinical information of 49 patients from 29 families (CD27 n=33, CD70 n=16), including 24 previously unreported individuals and identified a total of 16 distinct mutations in CD27, and 8 in CD70, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020006738DOI Listing
June 2020
10.452 Impact Factor

Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen mismatched donors.

Blood 2020 Jun 30. Epub 2020 Jun 30.

University of Washington, United States.

This trial aimed to evaluate the efficacy of sirolimus in addition to cyclosporine and mycophenolate mofetil for GVHD prophylaxis after nonmyeloablative conditioning for HLA class I or II mismatched Hematopoietic cell transplantation (HCT). Eligible patients had hematological malignancies treatable by allogeneic HCT. Conditioning consisted of fludarabine (90 mg/m2) and 2-3 Gy total body irradiation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020005338DOI Listing

CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity.

Blood 2020 Jun 20. Epub 2020 Jun 20.

Johns Hopkins University, Baltimore, Maryland, United States.

Multiple myeloma (MM) is a plasma cell neoplasm that commonly expresses CD38. Daratumumab (DARA), a human monoclonal antibody targeting CD38, has significantly improved the outcome of patients with relapsed and refractory MM, but the response is transient in most cases. Putative mechanisms of suboptimal efficacy of DARA include down-regulation of CD38 expression and over-expression of complement inhibitory proteins on MM target cells as well as DARA-induced depletion of CD38high natural killer (NK) cells resulting in crippled antibody dependent cellular cytotoxicity (ADCC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020006200DOI Listing

Outcome of Primary Mediastinal Large B-cell Lymphoma Using R-CHOP: Impact of a PET Adapted Approach.

Blood 2020 Jun 30. Epub 2020 Jun 30.

BC Cancer, Vancouver, British Columbia, Canada.

Cure rates for primary mediastinal large B-cell lymphoma (PMBCL) have improved with the integration of rituximab. However, the type of primary therapy and role of radiotherapy (RT) remains ill-defined. Herein, we evaluated the outcome of PMBCL primarily treated with R-CHOP and the impact of an end-of-treatment (EOT) FDG-PET scan to guide consolidative RT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2019004296DOI Listing

Changes in Bcl-2 members in response to ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL.

Blood 2020 Jun 30. Epub 2020 Jun 30.

Lymphoma and Myeloma Center Amsterdam, LYMMCARE, Netherlands.

Chronic lymphocytic leukemia (CLL) cells cycle between lymph node (LN) and peripheral blood (PB) and display major shifts in Bcl-2 family members between those compartments. Specifically, Bcl-XL and Mcl-1, which are not targeted by the Bcl-2 inhibitor venetoclax, are increased in the LN. Since ibrutinib forces CLL cells out of the LN, we hypothesized that ibrutinib may thereby affect expression of Bcl-XL and Mcl-1 and sensitize CLL cells to venetoclax. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2019004326DOI Listing

Pre-existing or Therapy-induced Mutations in Relapsed Acute Lymphoblastic Leukemia?

Blood 2020 Jun 30. Epub 2020 Jun 30.

University of Southern California, Keck School of Medicine, Los Angeles, California, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020005258DOI Listing

MYC-induced human acute myeloid leukemia requires a continuing IL3/GM-CSF co-stimulus.

Blood 2020 Jun 29. Epub 2020 Jun 29.

BC Cancer Agency, Vancouver, British Columbia, Canada.

Hematopoietic clones with leukemogenic mutations arise in healthy people as they age, but progression to acute myeloid leukemia (AML) is rare. Recent evidence suggests that the microenvironment may play an important role in modulating human AML population dynamics. To investigate this concept further, we examined the combined and separate effects of an oncogene (c-MYC) and exposure to IL3, GM-CSF and SCF on the experimental genesis of a human AML in xenografted immunodeficient mice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020006374DOI Listing

The BET inhibitor CPI203 promotes ex vivo expansion of cord blood long-term repopulating HSCs and megakaryocytes.

Blood 2020 Jun 29. Epub 2020 Jun 29.

University of Adelaide, Australia.

Although cytokine-mediated expansion of human hematopoietic stem cells (HSCs) can result in high yields of hematopoietic progenitor cells, this generally occurs at the expense of reduced bone marrow HSC repopulating ability thereby limiting potential therapeutic applications. As Bromodomain-containing proteins (BCPs) have been demonstrated to regulate mouse HSC self-renewal and stemness, we screened small molecules targeting various BCPs as potential agents for ex vivo expansion of human HSCs. Of 10 compounds tested, only the Bromodomain and Extra-terminal Motif (BET) inhibitor CPI203 enhanced the expansion of human cord blood HSCs without losing cell viability in vitro. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020005357DOI Listing

Key diagnostic markers for Autoimmune Lymphoproliferative Syndrome with molecular genetic diagnosis.

Blood 2020 Jun 29. Epub 2020 Jun 29.

Great Ormond Street Hospital, London, United Kingdom.

Autoimmune lymphoproliferative syndrome (ALPS) is a rare immunodeficiency caused by mutations in genes affecting the extrinsic apoptotic pathway (FAS, FASL, CASP10). This study evaluated the clinical manifestations, laboratory findings and molecular genetic results of 215 patients referred as possible ALPS. Double negative T-cell (DNT) percentage and in vitro apoptosis functional tests were evaluated by FACS; interleukin 10 and 18 (IL-10, -18) and soluble FAS ligand (sFASL) were measured by ELISA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020005486DOI Listing

Neutrophil Extracellular Traps (NETs) Contribute to Immunothrombosis in COVID-19 Acute Respiratory Distress Syndrome.

Blood 2020 Jun 29. Epub 2020 Jun 29.

Molecular Medicine Program, University of Utah, United States.

COVID-19 affects millions of patients worldwide with clinical presentation ranging from isolated thrombosis to acute respiratory distress syndrome (ARDS) requiring ventilator support. Neutrophil extracellular traps (NETs) originate from decondensed chromatin released to immobilize pathogens and can trigger immunothrombosis. We studied the connection between NETs and COVID-19 severity and progression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020007008DOI Listing
June 2020
10.452 Impact Factor

How I Treat Relapsed Acute Lymphoblastic Leukemia in the Pediatric Population.

Blood 2020 Jun 26. Epub 2020 Jun 26.

NYU Langone Medical Center, New York, New York, United States.

Relapsed acute lymphoblastic leukemia (ALL) has remained challenging to treat in children with survival rates lagging well behind those observed at initial diagnosis. Although there have been some improvements in outcomes over the past few decades, only approximately 50% of children with first relapse of ALL survive long term, and outcome are much worse with second or later relapses. Recurrences that occur within three years of diagnosis and any T-ALL relapses are particularly difficult to salvage. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2019004043DOI Listing

Synergistic Targeting of FLT3 Mutations in AML via Combined Menin-MLL and FLT3 Inhibition.

Blood 2020 Jun 26. Epub 2020 Jun 26.

University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.

The interaction of Menin (MEN1) and MLL (MLL1, KMT2A) is a dependency and potential therapeutic opportunity against NPM1-mutant (NPM1mut) and MLL-rearranged (MLL-r) leukemias. Concomitant activating driver mutations in the gene encoding the tyrosine kinase FLT3 occur in both leukemias and are particularly common in the NPM1mut subtype. Transcriptional profiling upon pharmacological inhibition of the Menin-MLL complex revealed specific changes in gene expression with downregulation of the MEIS1 transcription-factor and its transcriptional target gene FLT3 being most pronounced. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020005037DOI Listing

Plasmodium falciparum sexual parasites develop in human erythroblasts and affect erythropoiesis.

Blood 2020 Jun 26. Epub 2020 Jun 26.

Inserm U1016, CNRS UMR8104, Université de Paris, Paris, France.

Plasmodium falciparum gametocytes, the sexual stages responsible for malaria parasites transmission from humans to mosquitoes, are key targets for malaria elimination. Immature gametocytes develop in the human bone marrow parenchyma, where they accumulate around erythroblastic islands. Notably though, the interactions between gametocytes and this hematopoietic niche have not been investigated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2019004746DOI Listing

Interleukin-18 and cytotoxic impairment are independent and synergistic causes of murine virus-induced hyperinflammation.

Blood 2020 Jun 26. Epub 2020 Jun 26.

Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, Pennsylvania, United States.

Hemophagocytic Lymphohistiocytosis (HLH) and Macrophage Activation Syndrome (MAS) are life-threatening hyperinflammatory syndromes typically associated with underlying hematologic and rheumatic diseases, respectively. Familial HLH is associated with genetic cytotoxic impairment, and thereby to excessive antigen presentation. Extreme elevation of serum Interleukin (IL)-18 has been observed specifically in patients with MAS, making it a promising therapeutic target, but how IL-18 promotes hyperinflammation remains unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2019003846DOI Listing

Activation of the receptor tyrosine kinase, RET, improves long-term hematopoietic stem cell outgrowth and potency.

Blood 2020 Jun 26. Epub 2020 Jun 26.

The Francis Crick Institute, London, United Kingdom.

Expansion of Human Hematopoietic Stem Cells (HSCs) is a rapidly advancing field showing great promise for clinical applications. Recent evidence has implicated the nervous system and glial family ligands (GFLs) as potential drivers of hematopoietic survival and self-renewal in the bone marrow niche, but how to apply this to HSC maintenance and expansion is yet to be explored. We demonstrate a role for the GFL receptor, RET, at the cell surface of HSCs, in mediating sustained cellular growth, resistance to stress and improved cell survival throughout in vitro expansion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020006302DOI Listing

Rosetting T cells in Hodgkin lymphoma are activated by immunological synapse components HLA class II and CD58.

Blood 2020 Jun 26. Epub 2020 Jun 26.

University Medical Center Groningen, Groningen, Netherlands.

A unique feature of Hodgkin lymphoma (HL) is the presence of CD4+ T cells that surround, protect and promote survival of tumor cells. The adhesion molecules involved in this so-called T cell rosetting are important components of the immunological synapse (IS). However, it is unknown whether this synapse is fully assembled and leads to T cell activation by enabling interaction between the T cell receptor (TCR) and human leukocyte antigen class II (HLA-II). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020005546DOI Listing

Immune TTP pathogenesis: the rising sun on HLA.

Authors:
Paul Coppo

Blood 2020 Jun;135(26):2335-2336

French Reference Center for Thrombotic Microangiopathies.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020006078DOI Listing

NLP Hodgkin lymphoma: can we get away with less?

Blood 2020 Jun;135(26):2329-2330

Memorial Sloan Kettering Cancer Center.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020005876DOI Listing